Kenchappa RS, Dovas A, Argenziano MG, Meyer CT, Stopfer LE, Banu MA, Pereira B, Griffith J, Mohammad A, Talele S et al..  2022.  Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma.. Cell Rep. 39(12):110991.

Spinazzi EF, Argenziano MG, Upadhyayula PS, Banu MA, Neira JA, Higgins DMO, Wu PB, Pereira B, Mahajan A, Humala N et al..  2022.  Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.. Lancet Oncol. 23(11):1409-1418.

Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin Y-F et al..  2022.  De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.. Cancer Cell. 40(9):939-956.e16.

Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, De Nguyen Q-, Jones KL, Moreau LA, Peng J et al..  2022.  A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.. Cancer Cell. 40(9):957-972.e10.

Kohale IN, Yu J, Zhuang Y, Fan X, Reddy RJ, Sinnwell J, Kalari KR, Boughey JC, Carter JM, Goetz MP et al..  2022.  Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer.. Cancers (Basel). 14(17)

Stopfer LE, Rettko NJ, Leddy O, Mesfin JM, Brown E, Winski S, Bryson B, Wells JA, White FM.  2022.  MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.. Proc Natl Acad Sci U S A. 119(49):e2208900119.

Lopez BGC, Kohale IN, Du Z, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS et al..  2022.  Multimodal platform for assessing drug distribution and response in clinical trials.. Neuro Oncol. 24(1):64-77.

Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin J-R, Golby AJ et al..  2022.  Oncometabolite d-2HG alters T cell metabolism to impair CD8 T cell function.. Science. 377(6614):1519-1529.

Stopka SA, van der Reest J, Abdelmoula WM, Ruiz DF, Joshi S, Ringel AE, Haigis MC, Agar NYR.  2022.  Spatially resolved characterization of tissue metabolic compartments in fasted and high-fat diet livers.. PLoS One. 17(9):e0261803.

Stopfer LE, D'Souza AD, White FM.  2021.  1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs.. Immunooncol Technol. 11:100042.

Stopfer LE, Gajadhar AS, Patel B, Gallien S, Frederick DT, Boland GM, Sullivan RJ, White FM.  2021.  Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants.. Proc Natl Acad Sci U S A. 118(37)

Basu SS, Agar NYR.  2021.  Bringing Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging to the Clinics.. Clin Lab Med. 41(2):309-324.

Marin B-M, Porath KA, Jain S, Kim M, Conage-Pough JE, Oh J-H, Miller CL, Talele S, Kitange GJ, Tian S et al..  2021.  Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.. Neuro Oncol. 23(12):2042-2053.

Stopfer LE, Flower CT, Gajadhar AS, Patel B, Gallien S, Lopez-Ferrer D, White FM.  2021.  High-Density, Targeted Monitoring of Tyrosine Phosphorylation Reveals Activated Signaling Networks in Human Tumors.. Cancer Res. 81(9):2495-2509.

Leddy OK, White FM, Bryson BD.  2021.  Leveraging Immunopeptidomics To Study and Combat Infectious Disease.. mSystems. 6(4):e0031021.

Abdelmoula WM, Lopez BGimenez-Ca, Randall EC, Kapur T, Sarkaria JN, White FM, Agar JN, Wells WM, Agar NYR.  2021.  Peak learning of mass spectrometry imaging data using artificial neural networks.. Nat Commun. 12(1):5544.

Gerritsen JS, White FM.  2021.  Phosphoproteomics: a valuable tool for uncovering molecular signaling in cancer cells.. Expert Rev Proteomics. 18(8):661-674.

Kohale IN, Burgenske DM, Mladek AC, Bakken KK, Kuang J, Boughey JC, Wang L, Carter JM, Haura EB, Goetz MP et al..  2021.  Quantitative analysis of tyrosine phosphorylation from FFPE tissues reveals patient-specific signaling networks.. Cancer Res.

Stopfer LE, Conage-Pough JE, White FM.  2021.  Quantitative consequences of protein carriers in immunopeptidomics and tyrosine phosphorylation MS analyses.. Mol Cell Proteomics. :100104.

Shaaya M, Fauser J, Zhurikhina A, Conage-Pough JE, Huyot V, Brennan M, Flower CT, Matsche J, Khan S, Natarajan V et al..  2020.  Light-regulated allosteric switch enables temporal and subcellular control of enzyme activity.. Elife. 9

Randall EC, Lopez BGC, Peng S, Regan MS, Abdelmoula WM, Basu SS, Santagata S, Yoon H, Haigis MC, Agar JN et al..  2020.  Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma.. Cancer Res. 80(6):1258-1267.

Morshed N, Ralvenius WT, Nott A, L Watson A, Rodriguez FH, Akay LA, Joughin BA, Pao P-C, Penney J, LaRocque L et al..  2020.  Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration.. Mol Syst Biol. 16(12):e9819.

Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Lopez BGimenez-Ca, Connolly RM, Dunn IF, Van Poznak CH, Anders CK et al..  2020.  Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.. Clin Breast Cancer. 20(2):145-151.e2.

Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SKyun, Muhlich J, Chen J-Y, Vallabhaneni S, Baker GJ, Schapiro D et al..  2020.  Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.. Cell Syst. 11(5):478-494.e9.

Rockne RC, Hawkins-Daarud A, Swanson KR, Sluka JP, Glazier JA, Macklin P, Hormuth DA, Jarrett AM, Lima EABF, J Oden T et al..  2019.  The 2019 mathematical oncology roadmap.. Phys Biol. 16(4):041005.